Cargando…
Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs
BACKGROUND: Higher income population tend to prefer brand-name to generic drugs, which may cause disparity in access to brand-name drugs among income groups. A potential policy that can resolve such disparity is imposing a greater co-payment rate on high-income enrollees. However, the effects of suc...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824135/ https://www.ncbi.nlm.nih.gov/pubmed/31675967 http://dx.doi.org/10.1186/s12913-019-4598-8 |
_version_ | 1783464681258614784 |
---|---|
author | Ito, Yuki Hara, Konan Yoo, Byung-Kwang Tomio, Jun Kobayashi, Yasuki |
author_facet | Ito, Yuki Hara, Konan Yoo, Byung-Kwang Tomio, Jun Kobayashi, Yasuki |
author_sort | Ito, Yuki |
collection | PubMed |
description | BACKGROUND: Higher income population tend to prefer brand-name to generic drugs, which may cause disparity in access to brand-name drugs among income groups. A potential policy that can resolve such disparity is imposing a greater co-payment rate on high-income enrollees. However, the effects of such policy are unknown. We examined how patients’ choice between brand-name and generic drugs are affected by the unique income-based co-payment rates in Japan; 10% for general enrollees and 30% for those with high income among the elderly aged 75 and over. METHODS: We drew on cross-sectional price variation among commonly prescribed 311 drugs using health insurance claims data from a large prefecture in Japan between October 2013 and September 2014 to identify between-income-group differences in responses to differentiated payments. RESULTS: Running 311 multivariate logistic regression models controlling individual demographics, the median estimate indicated that high-income group was 3% (odds ratio = 0.97) less likely to choose a generic drug than the general-income group and the interquartile estimates ranged 0.92–1.02. The multivariate feasible generalized least squares model indicated high-income group’s higher likelihood to choose brand-name drugs than the general-income group without co-payment rate differentiation (p < 0.001). Such gap in the likelihood was attenuated by 0.4% (p = 0.027) with an US$1 increase in the difference in additional payment/month for brand-name drugs between income groups — no gap with US$10 additional payment/month. This attenuation was observed in drugs for chronic diseases only, not for acute diseases. CONCLUSIONS: Income-based co-payment rates appeared to reduce disparity in access to brand-name drugs across income groups, in addition to reducing total medical expenditure among high-income group who shifted from brand-name drugs to generic ones due to larger drug price differences. |
format | Online Article Text |
id | pubmed-6824135 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68241352019-11-06 Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs Ito, Yuki Hara, Konan Yoo, Byung-Kwang Tomio, Jun Kobayashi, Yasuki BMC Health Serv Res Research Article BACKGROUND: Higher income population tend to prefer brand-name to generic drugs, which may cause disparity in access to brand-name drugs among income groups. A potential policy that can resolve such disparity is imposing a greater co-payment rate on high-income enrollees. However, the effects of such policy are unknown. We examined how patients’ choice between brand-name and generic drugs are affected by the unique income-based co-payment rates in Japan; 10% for general enrollees and 30% for those with high income among the elderly aged 75 and over. METHODS: We drew on cross-sectional price variation among commonly prescribed 311 drugs using health insurance claims data from a large prefecture in Japan between October 2013 and September 2014 to identify between-income-group differences in responses to differentiated payments. RESULTS: Running 311 multivariate logistic regression models controlling individual demographics, the median estimate indicated that high-income group was 3% (odds ratio = 0.97) less likely to choose a generic drug than the general-income group and the interquartile estimates ranged 0.92–1.02. The multivariate feasible generalized least squares model indicated high-income group’s higher likelihood to choose brand-name drugs than the general-income group without co-payment rate differentiation (p < 0.001). Such gap in the likelihood was attenuated by 0.4% (p = 0.027) with an US$1 increase in the difference in additional payment/month for brand-name drugs between income groups — no gap with US$10 additional payment/month. This attenuation was observed in drugs for chronic diseases only, not for acute diseases. CONCLUSIONS: Income-based co-payment rates appeared to reduce disparity in access to brand-name drugs across income groups, in addition to reducing total medical expenditure among high-income group who shifted from brand-name drugs to generic ones due to larger drug price differences. BioMed Central 2019-11-01 /pmc/articles/PMC6824135/ /pubmed/31675967 http://dx.doi.org/10.1186/s12913-019-4598-8 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Ito, Yuki Hara, Konan Yoo, Byung-Kwang Tomio, Jun Kobayashi, Yasuki Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs |
title | Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs |
title_full | Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs |
title_fullStr | Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs |
title_full_unstemmed | Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs |
title_short | Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs |
title_sort | can income-based co-payment rates improve disparity? the case of the choice between brand-name and generic drugs |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824135/ https://www.ncbi.nlm.nih.gov/pubmed/31675967 http://dx.doi.org/10.1186/s12913-019-4598-8 |
work_keys_str_mv | AT itoyuki canincomebasedcopaymentratesimprovedisparitythecaseofthechoicebetweenbrandnameandgenericdrugs AT harakonan canincomebasedcopaymentratesimprovedisparitythecaseofthechoicebetweenbrandnameandgenericdrugs AT yoobyungkwang canincomebasedcopaymentratesimprovedisparitythecaseofthechoicebetweenbrandnameandgenericdrugs AT tomiojun canincomebasedcopaymentratesimprovedisparitythecaseofthechoicebetweenbrandnameandgenericdrugs AT kobayashiyasuki canincomebasedcopaymentratesimprovedisparitythecaseofthechoicebetweenbrandnameandgenericdrugs |